AbangeLabs

A new post-MI value threshold: empagliflozin reaches the boundary at €607 per year.

https://www.mattheneus.com/editorial/pubmed-empagliflozin-post-mi-heart-failure-risk-price-threshold-2026-10-05

#HTA #HealthEconomics #Pharma

Germany’s assessment of Lynkuet shows why comparative follow-up duration can determine whether symptom relief becomes credible added-benefit evidence. https://www.mattheneus.com/editorial/g-ba-elinzanetant-breast-cancer-endocrine-vasomotor-oasis4-duration-gap-2026-10-01 #HTA #Pharma #HealthEconomics

An intelligent knife may speed intraoperative cancer diagnosis, but adoption depends on comparative evidence linking accuracy to surgical and patient outcomes. https://www.mattheneus.com/editorial/pubmed-intelligent-knife-cancer-surgery-diagnostic-outcomes-evidence-gap-2026-10-06 #HTA #EvidenceSynthesis #Pharma

A Swedish haemophilia B model projects gene therapy dominance over factor prophylaxis, sharpening the debate on long-term value and uncertainty. https://www.mattheneus.com/editorial/pubmed-etranacogene-dezaparvovec-sweden-haemophilia-b-cost-effectiveness-2026-10-04 #HTA #HealthEconomics #Pharma

Germany’s final depemokimab decision highlights the evidentiary cost of an active-biologic comparator gap in severe nasal polyposis. https://www.mattheneus.com/editorial/g-ba-depemokimab-crswnp-final-resolution-active-biologic-comparator-gap-2026-10-01 #HTA #Pharma #RegulatoryAffairs

France’s reassessment of Kisqali at five-year follow-up shows how mature evidence can reshape perceived clinical value in early breast cancer. https://www.mattheneus.com/editorial/has-kisqali-ribociclib-early-breast-cancer-five-year-natalee-reassessment-2026-09-16 #HTA #Pharma #HealthEconomics

A three-year colorectal screening model projects $12.5 million in savings, showing how programme design can reshape both health outcomes and budgets. https://www.mattheneus.com/editorial/pubmed-next-generation-multitarget-stool-dna-idn-budget-model-2026-10-01 #HTA #HealthEconomics #Pharma

Poland’s positive Polpril Nebi advice shows how bioequivalence evidence and budget impact can align in reimbursement review. https://www.mattheneus.com/editorial/aotmit-polpril-nebi-final-positive-advice-budget-savings-2026-10-01 #HTA #Pharma #HealthEconomics

Australia’s PBAC recommends Palynziq after revised pricing, showing how financial arrangements can shift an HTA outcome. https://www.mattheneus.com/editorial/pbac-palynziq-final-outcome-financial-arrangement-2026-07 #HTA #Pharma #HealthEconomics

Which analgesics have the strongest early trial evidence in acute pancreatitis? A 13-trial review maps the choices. https://www.mattheneus.com/editorial/pubmed-acute-pancreatitis-early-analgesia-randomised-trials-2026-10-01 #HTA #EvidenceSynthesis #Pharma

The EMA's human medicines committee has backed Frehemgo for haemophilia A bleeding prophylaxis, adding a new factor VIII-mimetic option to the European landscape. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-frehemgo-denecimig-haemophilia-a-positive-opinion-fviii-mimetic-2026-09-17

Thailand’s luspatercept assessment sets a stark access benchmark: a 90.5% price reduction threshold. https://www.mattheneus.com/editorial/thailand-luspatercept-price-threshold-budget-impact-2026-09-28 #HTA #HealthEconomics #Pharma

France’s HAS grants durvalumab a minor added-benefit rating in resectable gastric and gastro-oesophageal junction cancer, translating MATTERHORN evidence into a measured access signal. https://www.mattheneus.com/editorial/has-imfinzi-durvalumab-resectable-gastric-gej-matterhorn-asmr-iv-2026-09-11 #HTA #Pharma #RegulatoryAffairs

Australia’s PBAC recommends subcutaneous amivantamab at intravenous price parity, highlighting how formulation convenience can shape reimbursement decisions. https://www.mattheneus.com/editorial/pbac-amivantamab-subcutaneous-exon20-lung-cancer-formulation-bridge-2026-07 #HTA #Pharma #RegulatoryAffairs